Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal doxorubicin + cyclophosphamide followed by nab-paclitaxel neoadjuvant trial in triple-negative breast cancer
ChiCTR1900021139Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Dec 2018
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of pegylated liposomal doxorubicin, cyclophosphamide and paclitaxel in breast cancer and triple-negative breast cancer (TNBC) (2 arms), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: pathological complete response. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
pegylated liposomal doxorubicincyclophosphamidepaclitaxel
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR1900021139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021139.